Alkem Laboratories: Intimation of incorporation of subsidiary in the form of Joint Venture
Alkem Laboratories (ALKEM) filed a disclosure titled "Intimation of incorporation of subsidiary in the form of Joint Venture". The company is valued at about ₹63,417 crore.
What happened
Alkem Laboratories (ALKEM) filed a disclosure with the exchanges on 8 November 2026 at 06:42 PM titled "Intimation of incorporation of subsidiary in the form of Joint Venture".
Company snapshot
Alkem Laboratories is a mid-cap company in the Healthcare sector, with a market value of about ₹63,417 crore.
The stock last traded at ₹5,304, against a 52-week range of ₹4,811–₹5,933.5 (10.6% below the high).
Before this filing the shares had moved −1.0% over the month and −5.8% over three months. Average daily turnover over the last 20 sessions was about ₹53.18 crore.
Promoters held 49.70% at the end of Q1 FY27, down 1.50% points from the previous quarter. Foreign institutions owned 10.42% and domestic institutions 22.63%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,371 | 664.3 | 55.56 |
| Q2 FY26 | 4,001 | 765.1 | 63.99 |
| Q3 FY26 | 3,737 | 636 | 53.19 |
| Q4 FY26 | 3,603 | 236.5 | 19.77 |
| Q1 FY27 | 3,740 | 520 | 43.49 |
What history shows
BCEIE's records show 4 previous m&a filings from the company since May 2026.
After those filings, the stock gained 1.5% on average the next trading day and was up 1.5% on average after five days (3 filings with price data).
Across 160 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.0% over five days; 59% of them rose the next day.
Market-wide, 2,376 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 17 Jul 2026 | Updates on Acquisition. | +2.1% | +0.9% |
| 29 Jun 2026 | M&A | +2.7% | +3.2% |
| 3 Jun 2026 | Dislcosure letter under Regulation 11(5) of The Securities and… | −0.4% | +0.5% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 12 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alkem names former Zydus executive Dr Amrut Naik new CEO
- ALKEM Outlook for the Week
- Tech Query: Alkem Laboratories, Intellect Design Arena, Trent, SRF — What is the outlook? Where are these stocks headed?
- Alkem Laboratories Appoints Sandip Darji as Vice President & Head – API Operations
- Bipin Lokegaonkar Joins Alkem Laboratories as Chief Information Security Officer
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.